Magazine Article | February 1, 2022

Why Cell & Gene Operating Models Need To Be As Innovative As Your Science

Source: Life Science Leader

By Omkar Kawalekar, Rohan Gupta, and Amit Agarwal

In the early stages of a cell and gene therapy (CGT) company’s evolution, the operating model is all about hiring and retaining key scientific/technical talent. Secondarily, it focuses on building an organizational structure that supports nimble decision-making by a small cohort of executives. Most early-stage CGT companies do not need or want a structured operating model that adds bureaucratic barriers and slows down the critical proof-of-concept achievement.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader